首页> 外文期刊>European Journal of Bioethics >Personalised medicine: Priority setting and opportunity costs in European public health care systems
【24h】

Personalised medicine: Priority setting and opportunity costs in European public health care systems

机译:个性化医疗:欧洲公共卫生保健系统中的优先级设置和机会成本

获取原文
       

摘要

“Personalised medicine” is currently attracting considerable attention and raising high hopes and expectations in modern medicine. The term “personalised medicine” denotes the use of genetic or other biomarker information, and it does not focus on a more personal patient-doctor relationship. Furthermore, personalised medicine is associated with ethical problems like priority setting and opportunity costs in solidarity-based public health care systems. Personalised medicine provides modern, highly specific and expensive diagnostics and treatments, which serve only limited subgroups of patients. At the same time, research in other fields of clinical medicine, which could be of benefit to more patients than such limited subgroups, remain underfunded.
机译:当前,“个性化医学”引起了人们的广泛关注,并在现代医学中提出了很高的希望和期望。术语“个性化医学”表示使用遗传或其他生物标记信息,并且不关注更个人化的医患关系。此外,个性化药物还与基于团结的公共卫生保健系统中的优先权设定和机会成本等道德问题相关。个性化医学提供了现代的,高度特异性的和昂贵的诊断和治疗方法,仅服务于部分患者。同时,与有限的亚组相比,可能对更多患者有益的其他临床医学研究仍缺乏资金。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号